61 results about "Pharmaceutics" patented technology

The present invention relates to a pharmaceutical dosage form comprising lanosterol and a derivative thereof, and cyclodextrin, the pharmaceutical dosage form according to one embodiment having an effect of improving water solubility and in vivo absorbability, thereby increasing bioavailability.

The invention discloses a double-drug-loading cationic mixed micelle as well as a preparation method and application thereof, and belongs to the field of pharmaceutics. The micelle is composed of a cationic polymer PEI-stearamide (PSA), an amphiphilic polymer DSPE-PEG2000, a hydrophobic drug resveratrol (RES) and a hydrophilic drug catalase (CAT). The preparation method comprises the following steps: 1) synthesizing PSA; the preparation method comprises 1, dissolving RES, PSA and DSPE-PEG2000 in an organic phase, injecting the obtained solution into a water phase, and carrying out rotary evaporation to obtain RES-loaded micelle (RES / PSA-PEG), and 3, adding a CAT solution to the micelle solution in a dropwise manner to obtain co-loaded micelle (RES / PSA-PEG / CAT). The micelle can effectively penetrate a corneal barrier and target a retinal pigment epithelial layer and a choroidal membrane.Through eye drop administration, RES anti-oxidation and anti-inflammatory effects and CAT hydrogen peroxide removal effects can be synergistically exerted, and an AMD curative effect can be substantially enhanced.

The invention discloses a chondroitin sulfate modified dihydromyricetin solid lipid nanoparticle, and belongs to the field of pharmaceutics. The nanoparticle is composed of a solid lipid component, dihydromyricetin encapsulated in the solid lipid component and a chondroitin sulfate targeting ligand modified on the surface. According to the invention, the chondroitin sulfate is specifically combined with the high-expression CD44 receptor on the surface of the hepatic stellate cell, so that the active targeting delivery of the drug to the hepatic fibrosis focus is realized. The nanoparticles have the characteristics of uniform particle size, high encapsulation efficiency and good slow release effect, can significantly improve the enrichment concentration of dihydromyricetin in the liver, enhance the anti-hepatic fibrosis curative effect and reduce the systemic side effects, and have good application prospects in preparation of hepatic fibrosis targeted therapy drugs.

The present invention relates to the technical field of pharmaceutics, and in particular to a triptolide lignocerate, a liposome thereof and a preparation method therefor. The chemical structural formula of the triptolide lignocerate is represented by formula (I). The triptolide lignocerate provided by the present invention is obtained by esterification of triptolide C14-OH and lignoceric acid. The anti-tumor effectiveness, safety and the like of the triptolide lignocerate liposome are further improved with respect to the prior art, so that a foundation is laid for providing safer and more effective triptolide-related clinical preparations.

The invention relates to a pharmaceutical composition for treating or improving intestinal leakage and / or blood-brain barrier injury induced by sleep deprivation and application of the pharmaceutical composition, and belongs to the field of medicines.The pharmaceutical composition is prepared from 5-60 parts of honey-fried licorice roots, 5-35 parts of dried ginger, 5-35 parts of radix paeoniae alba, 5-35 parts of cinnamon, 5-35 parts of pseudo-ginseng and 2-12 parts of leeches. The pharmaceutical composition disclosed by the invention can be processed into pharmaceutically acceptable oral dosage forms such as granules, powder and the like; the pharmaceutical composition provided by the invention can improve expression of tight junction protein of vascular endothelial cells and intestinal epithelial cells, reduce the level of blood-brain barrier and intestinal barrier injury markers in blood, improve expression of tight junction protein in blood-brain barrier and intestinal barrier of sleep deprivation patients, reduce influence caused by sleep insufficiency and improve sleep deprivation effect. A new thought is provided for treating the injury problem caused by sleep insufficiency in traditional Chinese medicine.

The present application relates to the technical field of pesticides, in particular to a kind of pyraclostrobin and prochloraz microemulsion and its preparation method and application, by weight percentage, including: pyraclostrobin 5-20%, prochloraz 20-40%, emulsifier 10%-34%, fertilizer compatible agent 6%-10%, solvent 5%-12%, cosolvent 8-15%, deionized water is made up to 100%.By adopting pyraclostrobin and prochloraz as effective active ingredients, under the action of specific emulsifier, fertilizer compatible agent, solvent and cosolvent, a microemulsion product with good pharmaceutical properties is obtained, which can cope with high and low temperature environment, adapt to various regional environments, transportation conditions and storage conditions, and the raw material is environmentally friendly, effectively reducing soil pollution, and has important significance for application in industry.

This invention discloses the application of the Miao medicine Liao's Huafengdan in the preparation of drugs for the prevention and treatment of multiple myeloma, belonging to the field of pharmaceutical application technology. In vitro detection using RPMI8226 and MM1.S multiple myeloma cells revealed that Liao's Huafengdan has a significant inhibitory effect on multiple myeloma. Flow cytometry analysis further showed its effect on cell apoptosis, indicating that Liao's Huafengdan significantly affects apoptosis in multiple myeloma cells, with higher drug concentrations leading to more pronounced apoptosis. Therefore, it can be used as a preparation for the prevention and treatment of multiple myeloma, and can be formulated into pharmaceutically permissible oral liquids, injections, tablets, capsules, and drop pills, providing a new application for Liao's Huafengdan. Moreover, Liao's Huafengdan is already a marketed drug and can be directly applied to humans without further clinical safety assessments, which can rapidly increase the market share of this product.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

The invention belongs to the field of pharmaceutics, and particularly relates to a composition containing budesonide and formoterol, and the composition provided by the invention is in a specific pH range, adopts a specific surfactant addition mode, also adopts moist heat sterilization, and is free of toxic and side effects. The prepared inhalation suspension of formoterol and budesonide has better delivery rate and total delivery amount, better fine particle fraction and smaller particle size distribution, has the advantages of low temperature, short time, strong penetrating power, economy, rapidness and the like compared with dry heat sterilization and moist heat sterilization, and is more suitable for industrial mass production.

The present invention relates to a use of a compound represented by formula (I) and a pharmaceutically acceptable salt thereof in the field of pharmaceutics, and in particular an application thereof in the preparation of a drug for treating pneumonia.

The invention belongs to the field of pharmaceutics, particularly relates to a composition containing levosalbutamol hydrochloride and ipratropium bromide as well as a preparation method and application of the composition, and overcomes the defects of a stabilizer disodium ethylene diamine tetraacetate adopted in the prior art. The invention provides a levosalbutamol hydrochloride and ipratropium bromide composition which is simpler in prescription and better in safety, can be used for treating reversible bronchospasm related to airway obstructive diseases, can jointly act on muscarinic acid and beta2 adrenergic receptors in the lung, can enhance the bronchiectasia effect, takes effect quickly, and is free of toxic and side effects. The clinical application value is very high.

The invention discloses a sodium hyaluronate composition and application of the sodium hyaluronate composition in preparation of medicines for preventing and treating knee osteoarthritis, and belongs to the field of medicines. The composition is an oral preparation, and the oral preparation is prepared from sodium hyaluronate, cortex acanthopanacis, caulis polygoni multiflori, radix achyranthis bidentatae, pawpaw, radix astragali and pharmaceutically acceptable auxiliary materials. Sodium hyaluronate is combined with'arthralgia-removing powder 'to treat knee osteoarthritis, and results of clinical tests show that by combining the two medicines, knee joint pain can be effectively relieved for a long time, knee joint activity can be improved, swelling can be eliminated, comprehensive functions of knee joints can be improved, patients do not relapse after drug withdrawal, and existing treatment effects can still be maintained.

The present invention relates to a salt and crystal form of an AT2R agonist and use thereof in pharmaceutics, and specifically relates to a salt and crystal form of methyl ((4-fluoro-5-isobutyl-3-(4-((2-(trifluoromethyl)-1H-imidazol-1-yl)methyl)phenyl)thiophen-2-yl)sulfonyl)carbamate (a compound represented by formula (I)) and use thereof in pharmaceutics.

The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and / or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.

The application discloses a nano-suspension preparation of juglone, which is mainly prepared from 5-15 parts of juglone and 1-20 parts of a stabilizer by weight. The application also adopts a reverse solvent method-high pressure homogenization method to establish a corresponding preparation method, which is simple in process and can obtain smaller drug particle size, thereby improving the drug bioavailability and enhancing the anti-tumor effect. Therefore, the application prepares a novel traditional Chinese medicine nano-preparation of juglone through the means of pharmacy, effectively improves the solubility and bioavailability of juglone. The in-vitro anti-tumor activity experimental results show that the nano-suspension preparation has significant inhibitory activity on the growth of various tumor cells, can be used for preparing drugs for preventing and treating related tumors, increases the targeting and bioavailability of the drug on tumors, reduces the toxicity, provides a new method and strategy for clinical treatment, and has good market prospect and high social value and economic value.

The inventions relate to medicine and pharmaceutics and can be used in the treatment of iron-deficiency anemia. A method for producing a composition of water-soluble readily absorbable bivalent iron includes dissolving an organic reducing compound in water and adding a source of iron(II), wherein the molar ratio of the organic reducing compound to the iron(II) source is from approximately 3:1 to 10:1. A composition of water-soluble readily absorbable bivalent iron is produced using the claimed method, and a hermetically sealed ampoule is used in a method for delivering said composition. The result is the fast and effective treatment of iron-deficiency anemia in patients.

The invention discloses a permeation-promoting and solubilizing meloxicam transdermal patch, and belongs to the field of pharmaceutics. The patch consists of a backing layer, a drug-loading pressure-sensitive adhesive layer and an anti-sticking layer, wherein the drug-loading pressure-sensitive adhesive layer consists of a solvent type pressure-sensitive adhesive, meloxicam, a penetration enhancer and a solubilizer. According to the patch, transdermal delivery of meloxicam is achieved, various penetration enhancers and solubilizers are systematically screened, so that meloxicam in the patch is continuously administered at a proper transdermal permeation rate, effective blood concentration can be maintained in a relatively prolonged time, the administration frequency is reduced, and the problem that the in-vitro accumulated permeation amount of the meloxicam patch is low is solved. The meloxicam patch has the characteristics of high percutaneous penetration amount and continuous administration, and is effectively used for skin administration treatment of osteoarthritis and rheumatoid arthritis.

This invention relates to a pharmaceutical formulation and more particularly to one for Active Pharmaceutical Ingredients (APIs) which are recognised under the Biopharmaceutical Classification System (BCS) as a Class I, III or III drug. In addition to the API, it comprises a combination of gelling agents comprising: a primary gelling agent which is agar and a secondary gelling agent which is an alginate together with at least one cation donator, a preservative, and water and optionally a thickening agent, sweetener(s) and flavouring.

The present disclosure pertains to universal and adoptable cell culture substrates designed for applications in biology, medicine, pharmaceutics, and other relevant fields. The disclosure particularly focuses on processes and methodologies for manufacturing such substrates, which prove advantageous for both non-neural (cells exhibiting robust adhesion and weak cell-cell junctions, as well as cells with regular adhesion and cell-cell junctions) and neural cell sheet engineering. These substrates aim to enhance cell adhesion, stimulate cell growth, and enable rapid and uniform harvesting of cell sheets. Additionally, the present invention introduces a scaffold-free method for tissue engineering, facilitating the creation of a 2D / 3D neural tissue construct featuring unidirectional neuron bundles.

The invention discloses an application of a Yindan Xinnaotong soft capsule in preparation of a medicine for treating type 2 diabetes mellitus, a luciferase reporter gene plasmid is constructed by targeted targeting of a glucagon-like peptide-1 receptor (GLP-1R), which is one of the most effective targets for treating the type 2 diabetes mellitus at the present stage, HEK-293T is used as a tool cell in vitro, and the application of the Yindan Xinnaotong soft capsule in preparation of the medicine for treating the type 2 diabetes mellitus is realized. GLP-1R luciferase reporter gene plasmids are transfected into the GLP-1R promoter, and luciferase reporter gene experiments find that the Yindan Xinnaotong soft capsule can significantly up-regulate the activity of the GLP-1R promoter. Furthermore, verification is carried out through in-vitro and in-vivo experiments, and results show that the Yindan Xinnaotong soft capsule has a certain protection effect on MIN6 cells damaged by palmitic acid and has a remarkable improvement effect on glucolipid metabolism of mice with type 2 diabetes by influencing a GLP-1R signal channel, so that the Yindan Xinnaotong soft capsule can be used as a preparation for treating the type 2 diabetes and has a good application prospect. The traditional Chinese medicine composition can be prepared into oral liquid, injection, tablets, capsules, granules, dripping pills and the like which are permissible in pharmacy.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from amlodipine, empagliflozin, folic acid substances and a pharmaceutically acceptable carrier, wherein the amlodipine, the empagliflozin and the folic acid substances are in medicinal effective dose. The invention also provides application of the pharmaceutical composition in preparation of medicines for treating lower limb artery occlusion diseases.

The present invention relates to a compound represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic thereof, and an intermediate and a pharmaceutical composition thereof, and use thereof in Bcl6-related diseases such as cancer. B-L-K (I).

The present disclosure relates to the field of pharmaceutics and particularly provides a sustained-release pharmaceutical composition of sivelestat and a preparation method therefor. The pharmaceutical composition included sivelestat and a phospholipid. The present disclosure uses sivelestat, which is poorly soluble in water, as an active ingredient and the phospholipid as a stabilizer. Particles of sivelestat have excellent aerodynamic performance, good stability, a small amount of auxiliary materials, and a simple preparation process. After inhalation, the drug stays in the lungs for a long time and has a good sustained-release effect and a good industrial production prospect.

The invention relates to a method for providing a water-soluble adduct and an ibuprofen adduct, wherein the membrane permeability of the adduct is improved and the classification according to the Biopharmaceutics Classification System is influenced.

The invention discloses a traditional Chinese medicine beverage capable of soothing nerves, helping sleep and regulating emotion and a preparation method thereof, and particularly relates to the field of traditional Chinese medicine pharmaceutics. The beverage realizes sleep aiding through jujuboside, spinosin, eleutheroside, cyclic adenosine monophosphate and the like, regulates emotion through fingered citron lactone, rose volatile oil and the like, and tranquilizes and stabilizes mind by using hericium erinaceus, hawthorn flavone and the like. The preparation method comprises the following steps: carrying out differential pretreatment on raw materials; volatile oil, water-soluble functional components and flavor substances are obtained through circulating percolation extraction, dynamic countercurrent extraction and mild extraction by adopting a stepped directional extraction process; and precisely filtering and clarifying the extracting solution through a ceramic membrane, compounding with aromatic volatile oil, and sterilizing and filling by adopting a 550MPa ultrahigh-pressure cold sterilization technology. The method overcomes the defects of low extraction efficiency and easy loss of active components in the traditional process, realizes efficient synergistic extraction and complete retention of various active components, and has the advantages of fresh taste, stable character, long shelf life and accurate and controllable process parameters.

The group of inventions relates to chemistry, medicine and pharmaceutics, and more particularly to a liquid aerosol composition for the protection of wounds and to a wound protection method. The proposed liquid aerosol composition comprises a film-forming solution of a polymer in an organic solvent, and a propellant, wherein the film-forming solution consists of 2-5 wt.% styrene-ethylene-butylene-styrene (SEBS) block copolymer and 95-98 wt.% organic solvent selected from among dichloromethane, cyclohexane or a mixture thereof, and the propellant is a hydrocarbon propellant or dimethyl ether. According to the proposed method, the liquid aerosol composition is applied to the surface of a wound from a distance of 10-20 cm for 10-15 seconds by spraying from an aerosol can, wherein a polymer film is formed within 30-60 seconds and the formed polymer film has a thickness of 0.006-0.010 mm. The group of inventions provides an elastic film which has good adhesive properties and an optimal moisture vapour transmission rate.

This invention provides a yin-nourishing and blood-tonifying medicinal composition, its preparation method, and its application, belonging to the technical field of traditional Chinese medicine compositions. The active ingredients of this composition are prepared from the following raw materials in parts by weight: Astragalus membranaceus 2-3 parts, Angelica sinensis 12-18 parts, Crataegus pinnatifida 2-3 parts, Glycyrrhiza uralensis 2-5 parts, Chrysanthemum indicum 5-9 parts, Melon japonica 20-30 parts, Lemon 15-19 parts, Fine corn flour 2-3 parts, and Whole milk powder 40-44 parts, wherein the weight ratio of Angelica sinensis to Astragalus membranaceus is (6-9):1. The composition of this invention can be prepared into various oral preparations using conventional pharmaceutical processes. The preparation process is stable and controllable, suitable for industrial production. This composition possesses the effects of nourishing yin and blood, strengthening the spleen and promoting digestion, is safe with no toxic side effects, and has an excellent taste. It can be used to prepare drugs for treating and improving yin and blood deficiency syndromes, and has good clinical application and industrialization prospects.

The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-cyclodextrin powder for injection, comprising sulfobutylether-β-cyclodextrin, which can significantly improve the solubility, safety, and dilution stability of nimodipine, and increase patient compliance and the convenience of clinical use. Compared with a commercially available nimodipine injection NIMOTOP, the present invention has significant advantages in safety and dilution stability.

The invention discloses a preparation method of a traditional Chinese medicine composition for treating chronic arrhythmia. The traditional Chinese medicine composition is prepared from rhizoma corydalis, rhizoma galangae, radix curcumae, fructus piperis longi, rhizoma zingiberis and cortex cinnamomi, and volatile oil is extracted from the rhizoma galangae, the rhizoma zingiberis and the cortex cinnamomi; decocting rhizoma corydalis, radix curcumae and fructus piperis longi with water to obtain an aqueous extract; and mixing the volatile oil and the water extract, and drying to prepare a solid preparation. According to the preparation method disclosed by the invention, on the basis of inheriting the classic traditional Chinese medicine, modern scientific and technological means are applied, the traditional Chinese medicine pharmacy characteristic theoretical level and the preparation process technology are innovatively developed, and a'three-effect three-small five-convenient '(efficient, quick-acting and long-acting; dosage, toxicity and side effects are small; the modern traditional Chinese medicine preparation which is convenient to take, carry, store, produce and transport meets the requirements and the actual requirements of the age development, and the traditional Chinese medicine composition (the rhizoma zingiberis recens slices) prepared according to the method disclosed by the invention has the advantages of obviously improved curative effect, convenience in carrying, simplicity and rapidness in taking and high patient compliance.

This application relates to the field of traditional Chinese medicine pharmaceutics technology, specifically disclosing a cold-maceration preparation method for fermented medicinal wine. The method includes the following steps: S1, pulverizing a traditional Chinese medicine composition to obtain coarse powder, wherein the composition includes a principal drug array, an assistant drug array, a adjuvant drug array, and a guiding drug array, and the principal drug array is made from raw materials containing the following parts by weight: 8-12 parts artificial musk, 45-55 parts camphor, and 45-55 parts borneol; S2, mixing the coarse powder obtained in S1 with white wine, sealing and soaking to obtain an soaking mixture; S3, opening the seal and stirring the soaking mixture obtained in S2 to obtain fermented medicinal wine. The cold-maceration preparation method for fermented medicinal wine of this application has the unique advantages of a clear distinction between the principal, assistant, adjuvant, and guiding drug layers in the formulation design, synergistic effects, and a preparation process that can fully and stably extract the effective components of each drug array, resulting in a medicinal wine with concentrated and targeted medicinal power, especially suitable for dispelling deep-seated cold pathogens and clearing meridian blockages.